Investment summary

ProMetic’s investment case rests on deriving greater value from proprietary ligand enabling technologies by moving up the value chain and developing higher-value/less-commoditised technologies. With improved near-term visibility, ProMetic expects stronger revenues in 2012 supported by confirmed purchase orders (eg $2.5m in H112 for octaplasLG) and service revenues (c $2.5m for multinational biopharma product scale up). The balance sheet has been improved by a secured loan restructuring, $1m strategic equity investment and achievement of final Celgene milestones (allowing deferred recognition of US$6m). Business focus is on validating the plasma-derived therapies manufacturing subsidiary, boosting resin sales, and securing further partners for its novel oral small molecule drugs.

Last updated on 23/04/2012

Industry outlook

Other catalysts with the potential to boost revenues and sentiment include product development partnerships, European commercialisation of the P-Capt prion reduction filter, and securing its funding base.

Last updated on 23/04/2012